When Is FDA Form 1932 Required? (w/Examples) + FAQs

FDA Form 1932 is required when a foreign government or entity requests official certification that a product, establishment, or device complies with U.S. Food and Drug Administration regulations for export purposes. This certificate serves as proof that an FDA-regulated product meets specific regulatory standards in the United States.

The need for Form 1932 stems from international trade agreements and foreign regulatory requirements that mandate verification of product compliance before allowing entry into their markets. Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), Section 801(e)(1), the FDA can issue export certificates, but the agency has established strict procedural requirements through 21 CFR Part 1 that create a complex verification process. Without proper certification, products face immediate rejection at foreign customs, resulting in shipment delays, financial losses, and damaged business relationships with international partners.

According to FDA data, the agency processes over 20,000 export certificate requests annually, with approximately 15% facing delays or rejections due to incomplete documentation or incorrect form submissions.

What You’ll Learn:

🎯 When federal law mandates Form 1932 — including the specific regulatory triggers for drugs, devices, cosmetics, and food products that require certification before export

📋 How to complete every section correctly — detailed guidance on each form field, required attachments, and the consequences of errors that cause processing delays

⚖️ Which products need certification — clear distinctions between items requiring Form 1932 versus alternative export documentation across different FDA-regulated categories

🌍 Country-specific requirements — what destination nations demand beyond basic FDA certification and how to navigate multiple regulatory frameworks simultaneously

💡 Common mistakes that cause rejections — the most frequent errors companies make when requesting export certificates and how to avoid costly resubmissions

Understanding FDA Form 1932: The Certificate to Foreign Government

FDA Form 1932 represents the official document that certifies information about FDA-regulated products to foreign governments. The form serves as a bridge between U.S. regulatory compliance and international market access requirements.

The FDA issues this certificate only after verifying that the product, establishment, or device meets specific criteria outlined in federal regulations. The certificate program operates under the authority granted by the FD&C Act, which permits the agency to assist U.S. companies in meeting foreign regulatory requirements.

Foreign governments require these certificates because they lack direct access to FDA inspection records, compliance databases, and regulatory status information. The certificate acts as an official statement from the U.S. government that validates claims made by exporters about their products.

The form itself contains several critical sections that capture product details, manufacturer information, intended destination, and specific certifications requested by the foreign authority. Each section requires precise information that matches FDA records exactly, as discrepancies trigger automatic rejections.

Who Issues and Processes Form 1932

The FDA’s Division of Import Operations and Policy (DIOP) within the Office of Regulatory Affairs handles all export certificate requests. This centralized processing ensures consistency in how the agency evaluates applications and issues certificates.

Companies cannot obtain Form 1932 from state agencies, customs brokers, or third-party consultants. The federal government maintains exclusive authority over issuing export certificates to prevent fraud and ensure authenticity.

The processing timeline typically ranges from five to twenty business days, depending on the complexity of the request and the completeness of submitted documentation. Rush processing options exist for urgent shipments, but these require additional fees and compelling justification.

When Federal Law Mandates Form 1932

The requirement for Form 1932 arises from two distinct sources: foreign government demands and U.S. export regulations. Understanding both triggers helps companies avoid compliance gaps.

Foreign Government Requirements

Most countries require export certificates for FDA-regulated products before granting import approval. These requirements appear in foreign laws, regulations, or administrative policies that govern product entry.

The European Union, for example, requires certificates for certain pharmaceuticals and medical devices under EU Directive 2001/83/EC, which mandates proof of manufacturing compliance with international standards. Japanese authorities request certificates under the Pharmaceuticals and Medical Devices Act to verify that products sold in the U.S. meet equivalent safety standards.

China’s National Medical Products Administration (NMPA) requires export certificates for drugs and devices as part of their registration process. Canadian authorities request certificates to confirm that products comply with U.S. regulations before considering them for approval under their own regulatory framework.

Each country structures its requirements differently. Some nations demand certificates for all FDA-regulated products, while others limit requirements to specific categories like prescription drugs or Class III medical devices.

U.S. Export Compliance Framework

Federal law creates specific scenarios where Form 1932 becomes necessary regardless of foreign government requests. These situations arise from the structure of U.S. export regulations.

Products that are not approved for U.S. market sale but qualify for export under Section 802 of the FD&C Act often require certification. The export provisions allow unapproved products to leave the country if they meet foreign requirements, but foreign authorities typically demand proof that the FDA permits the export.

Establishments subject to FDA inspection need certificates to demonstrate their compliance status. Foreign regulators want confirmation that manufacturing facilities maintain current Good Manufacturing Practice (cGMP) standards and have no outstanding warning letters or regulatory violations.

Products with unique regulatory classifications in the U.S. require certificates to explain their status to foreign authorities. A combination product that contains both a drug and a device, for instance, needs certification clarifying which FDA center regulates it and what approval pathway it followed.

Product Categories Requiring Form 1932

Different FDA-regulated product types face varying certification requirements based on their regulatory classification and the destination country’s rules.

Prescription and Over-the-Counter Drugs

Pharmaceutical products represent the largest category of Form 1932 requests. Both prescription medications and over-the-counter drugs require certificates when exporting to countries with mutual recognition agreements or strict import controls.

New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs) need certification to verify their approval status with the FDA. Foreign regulators examine these certificates to determine whether products have undergone rigorous safety and efficacy testing in the U.S.

Investigational drugs moving internationally for clinical trials require special certificates. The FDA must confirm that the Investigational New Drug application is active and that the proposed trial complies with U.S. regulations, even though the drug itself lacks marketing approval.

Generic drugs face unique challenges because foreign authorities want confirmation that the product is therapeutically equivalent to the reference listed drug. The certificate must specify the Orange Book rating and explain any differences between the U.S.-approved formulation and the export version.

Compounded medications generally cannot receive export certificates unless they meet specific criteria outlined in Section 503A or 503B of the FD&C Act. The FDA carefully evaluates whether compounded products qualify as acceptable exports under federal law.

Medical Devices Across All Classifications

Medical devices require Form 1932 based on their risk classification and the regulatory pathway they followed to reach the U.S. market. Class I, II, and III devices each face different certification scenarios.

Class III devices, which pose the highest risk, almost always need certificates for export. These products require Premarket Approval (PMA) before U.S. sale, and foreign governments want verification of this rigorous review process.

Class II devices cleared through the 510(k) pathway need certificates when exporting to countries that recognize FDA clearance as evidence of safety and effectiveness. The certificate confirms the device’s classification, the predicate device it was compared against, and any special controls that apply.

Class I devices generally face fewer certification requirements, but exceptions exist. If a foreign country specifically requests confirmation that a Class I device is exempt from premarket review, the FDA can issue a certificate stating this exemption status.

In vitro diagnostic devices require certificates that clarify their regulatory status because many countries categorize these products differently than the U.S. does. The certificate explains whether the FDA regulates the device under CLIA, as a medical device, or through another pathway.

Custom devices manufactured for specific patients rarely qualify for export certificates because they do not undergo traditional FDA review. The agency evaluates these requests case-by-case based on the destination country’s specific needs.

Biologics and Vaccine Products

Biological products licensed under Section 351 of the Public Health Service Act require certificates that verify their Biologics License Application (BLA) approval status. These products include vaccines, blood components, gene therapies, and cellular products.

Vaccines face particularly complex certification requirements because destination countries often want detailed information about manufacturing processes, quality control testing, and lot release procedures. The FDA certificate must confirm that the Center for Biologics Evaluation and Research has approved the product and continues to monitor its safety.

Blood and blood components need certificates that address both the product itself and the collection facility. Foreign authorities want verification that blood centers comply with FDA regulations for donor screening, testing, and processing.

Gene therapy products require certificates explaining their unique regulatory status. The FDA must clarify whether it regulates the product as a biological product, a drug, or both, and describe any special conditions attached to the approval.

Biosimilar products need certificates that distinguish them from reference products. The certificate must explain the FDA’s determination of biosimilarity and any differences in approved indications or patient populations.

Cosmetics and Personal Care Products

Cosmetic products generally do not require FDA approval before marketing in the U.S., which creates unique certification challenges. The FDA can issue certificates confirming that a cosmetic is not adulterated or misbranded under Section 601 of the FD&C Act, but cannot certify safety or effectiveness.

Color additives used in cosmetics need certificates verifying their approval status. The FDA maintains a list of approved color additives, and certificates confirm that products use only permitted substances in allowed concentrations.

Products marketed as both cosmetics and drugs (such as anti-dandruff shampoos or sunscreens) require certificates that explain their dual status. The FDA must clarify which regulatory requirements apply to each aspect of the product.

Cosmetic manufacturers seeking certificates face the challenge that FDA registration is voluntary. If a company has not registered its facility or listed its products with the FDA, obtaining a certificate becomes more difficult because the agency has limited information to verify.

Food Products and Dietary Supplements

Food products rarely require Form 1932 for export, but specific situations trigger the need for certification. Food facilities subject to the Food Safety Modernization Act (FSMA) may need certificates confirming their registration status and compliance history.

Dietary supplements face unique requirements because they occupy a regulatory space between foods and drugs. Foreign countries often regulate these products as pharmaceuticals, creating demand for certificates that explain their U.S. regulatory status under the Dietary Supplement Health and Education Act.

Infant formula products require certificates verifying that manufacturers comply with specific nutrient requirements and quality control standards mandated by federal regulations. The FDA must confirm that the formula meets the legal definition and nutritional specifications.

Low-acid canned foods need certificates confirming that the processing facility has filed required process information and operates under appropriate thermal processing controls. These certificates address food safety concerns specific to canned product manufacturing.

Irradiated foods may require certificates explaining the irradiation source, dose levels, and FDA approval status. Some countries restrict or prohibit irradiated food imports, making accurate certification critical.

The Three Most Common Certification Scenarios

Understanding real-world situations where companies need Form 1932 helps clarify when to initiate the certification process and what documentation to prepare.

Scenario One: New Market Entry for Approved Drugs

A pharmaceutical company with an FDA-approved blood pressure medication wants to enter the Brazilian market. Brazil’s National Health Surveillance Agency (ANVISA) requires proof that the drug is approved in the country of origin before considering it for registration.

The company must request Form 1932 from the FDA certifying the drug’s NDA approval status. The certificate needs to confirm the approved indications, dosage forms, and strengths. ANVISA also requires verification that the manufacturing facility maintains current cGMP compliance and has no outstanding regulatory violations.

The company submits the request with the NDA number, manufacturing facility registration number, and specific certification language requested by ANVISA. Processing takes approximately fifteen business days, after which the FDA issues the certificate with an official seal and signature.

The certificate becomes part of the company’s registration dossier submitted to ANVISA. Without this certification, ANVISA will not begin the review process, effectively blocking market entry until proper documentation is provided.

Scenario Two: Medical Device Export Under Section 802

A medical device manufacturer develops an advanced cardiac monitor that incorporates features not yet approved for the U.S. market. A hospital in India wants to purchase the device, but Indian regulatory authorities require FDA certification before approving the import.

The device qualifies for export under Section 802 of the FD&C Act because it meets India’s regulatory requirements, even though it lacks U.S. marketing approval. The manufacturer must request Form 1932 that certifies the FDA permits the export and explains the device’s regulatory status.

The certificate must clearly state that the device is not approved for sale in the United States but is legally exported under Section 802 provisions. It should specify the device classification, identify the Indian regulatory approval it will pursue, and confirm that the manufacturer notified the FDA of the export.

The manufacturer submits documentation showing the device meets Indian standards and includes a letter from the Indian hospital confirming their intent to purchase. The FDA reviews the request to ensure it complies with export regulations before issuing the certificate.

This certification allows the manufacturer to access international markets while continuing U.S. approval efforts. Without the certificate, the device would be detained at Indian customs regardless of its compliance with local regulations.

Scenario Three: Cosmetic Product International Distribution

A cosmetics company wants to export a line of lipsticks containing specific color additives to several European Union member states. EU regulations require certification that color additives used in cosmetics comply with the exporting country’s regulations.

The company requests Form 1932 certifying that all color additives in their lipstick formulations appear on the FDA’s list of approved color additives for cosmetics. The certificate must specify each color additive by name and certification number, confirming they are permitted for use in products applied to the lips.

The EU also requires confirmation that the manufacturing facility is not under any FDA warning letters or import alerts. The company provides its facility registration number (if registered) and requests a statement that the facility has no outstanding compliance actions.

The certificate cannot state that the FDA has approved the lipstick products because the agency does not approve cosmetics before marketing. Instead, it confirms that the products comply with U.S. requirements for cosmetic safety and labeling under the FD&C Act.

This distinction is critical because foreign regulators need to understand that U.S. cosmetic regulation operates differently from pharmaceutical regulation. The certificate must clearly explain what the FDA does and does not verify for cosmetic products.

Step-by-Step Guide to Completing FDA Form 1932

Filling out Form 1932 requires attention to detail because errors or omissions cause processing delays and potential rejections. Each section serves a specific purpose in the certification process.

Section 1: Applicant Information

This section captures details about the person or company requesting the certificate. The applicant is typically the U.S. manufacturer, exporter, or their authorized representative.

Enter the complete legal name of the applicant exactly as it appears in FDA registration records. Trade names or “doing business as” designations should be avoided unless they match official FDA records precisely.

Provide a complete street address, not a post office box. The FDA uses this address to verify the applicant’s identity and may send correspondence to this location. The address must match the address on file with the FDA for the registered establishment if the applicant is the manufacturer.

Include a direct phone number and email address for the person handling the export certificate request. The FDA contacts applicants when questions arise or additional information is needed, and providing accurate contact information prevents unnecessary delays.

The applicant signature section requires an original signature from an authorized representative. Electronic signatures are acceptable if the submission occurs through the FDA’s electronic systems, but handwritten signatures are required for paper submissions.

Section 2: Product Information

This section requires detailed information about the product being exported. Accuracy is critical because the FDA verifies this information against its databases.

Specify the product name exactly as it appears in the FDA approval or registration. For drugs, use the proprietary name if applicable, along with the established name. For devices, provide the trade name and common or usual name.

Enter the applicable FDA application or registration number. For drugs, this is the NDA, ANDA, or Biologics License Application (BLA) number. For devices, provide the 510(k) number, PMA number, or establishment registration number. For establishments without specific product approvals, use the Food Facility Registration number or Device Establishment Registration number.

Describe the dosage form (for drugs), device type, or product category clearly. The description should match the language used in the FDA approval or registration documents to avoid confusion.

List all active ingredients for drugs or materials for devices. The FDA verifies that these match approved formulations, so discrepancies will trigger questions or rejections.

Section 3: Manufacturing Information

This section identifies where the product is manufactured and the compliance status of the facility. Foreign authorities pay close attention to this information when evaluating product quality.

Provide the complete name and address of the manufacturing facility exactly as it appears in FDA registration records. If multiple facilities are involved in manufacturing, list the final manufacturing facility where the product takes its finished form.

Enter the FDA Establishment Identifier (FEI) number for the facility. This unique number allows the FDA to quickly access inspection history, compliance records, and registration status.

Indicate the date of the most recent FDA inspection if applicable. Many countries want recent inspection data to confirm ongoing compliance with quality standards.

Check the appropriate box indicating whether the facility is currently in compliance with applicable regulations. If the facility has outstanding warning letters, untitled letters, or import alerts, this must be disclosed. Failing to disclose compliance issues can result in certificate revocation and potential fraud charges.

Section 4: Destination and Purpose

This section captures information about where the product is going and why the certificate is needed. This helps the FDA understand the context for the certification request.

Identify the destination country clearly. Use the official country name, not abbreviations or regions. If the product will pass through multiple countries during shipping, list the final destination country, not transit locations.

Provide the name and address of the foreign purchaser or consignee if known. Some countries require this information on the certificate itself, while others simply want it for FDA records.

Explain the purpose of the export. Common purposes include commercial sale, clinical trial, regulatory registration, or exhibition. The purpose affects what certifications the FDA can provide.

Indicate the quantity being exported if the foreign authority requires this information on the certificate. Some countries want to ensure that exports match declared quantities for customs purposes.

Section 5: Specific Certification Requested

This is the most critical section because it determines what statements the FDA will make on the certificate. The specific language often comes from the foreign regulatory authority’s requirements.

Many foreign governments provide exact certification language they need on the certificate. Include this language verbatim in the space provided. The FDA will review the requested language to ensure it can truthfully make the stated certifications.

Common certification statements include confirmation that the product is approved for marketing in the U.S., that the manufacturing facility complies with cGMP requirements, that the establishment is registered with the FDA, or that the product is legally exported under Section 802.

The FDA cannot certify statements that are false, misleading, or beyond its regulatory authority. For example, the agency cannot certify that a product is “safe and effective” for cosmetics because it does not approve cosmetics for safety and efficacy.

If the foreign authority does not provide specific language, request a standard certification statement appropriate for the product type. The FDA has template language for common certification scenarios.

Section 6: Supporting Documents

This section lists additional documentation that must accompany the Form 1932 submission. The required documents vary based on product type and the certification requested.

For approved drugs, include a copy of the approval letter from the FDA. This document proves the product’s regulatory status and provides details about approved indications and manufacturing specifications.

For medical devices, attach the 510(k) clearance letter, PMA approval order, or statement of exemption. These documents verify the device’s regulatory pathway and current status.

Provide a copy of the product label as marketed in the U.S. or as intended for export. Foreign authorities often compare the label to their own requirements, and the FDA uses it to verify product identity.

Include documentation of the specific certification language requested by the foreign government. This might be a regulatory requirement document, an official letter, or a form provided by the foreign authority. Having this documentation helps the FDA understand what the foreign government needs.

For products exported under Section 802, submit evidence that the product meets the destination country’s requirements. This might include test results, foreign approval letters, or standards compliance documentation.

Section 7: Fees and Payment

The FDA charges fees for processing export certificate requests. The current fee structure is outlined in the FDA Export Certificate Fee Schedule, which is updated annually.

Standard processing typically costs between $175 and $250 per certificate, depending on the product type and complexity of the request. Rush processing fees range from $400 to $500 for expedited turnaround within five business days.

Payment must accompany the application. The FDA accepts checks, money orders, and electronic payments through the FDA Payment Portal. Credit card payments are accepted for online submissions.

Include the payment confirmation number or attach a copy of the check or money order. Applications submitted without proper payment are returned without processing, causing significant delays.

Fee waivers are rarely granted but may be available for humanitarian purposes or when certification supports public health initiatives in developing countries. Waiver requests require detailed justification and supporting documentation.

Mistakes to Avoid When Requesting Form 1932

Companies frequently make errors that delay or prevent certificate issuance. Understanding these common mistakes helps ensure successful processing.

Using Outdated Form Versions: The FDA periodically updates Form 1932, and submitting an old version causes automatic rejection. Always download the current form from the official FDA website immediately before completing it. Using a form saved to a computer months earlier may result in using an obsolete version.

Mismatching Product Information: Entering product details that do not exactly match FDA records creates verification problems. A drug name spelled slightly differently, a missing hyphen in a device name, or an incorrect formulation strength will halt processing. The FDA cannot proceed until the applicant corrects the discrepancy and confirms which information is accurate.

Requesting Impossible Certifications: Asking the FDA to certify statements beyond its authority results in rejection. The agency cannot certify that a product is “the best” in its class, that it has “no side effects,” or that it is “approved by the World Health Organization.” Only request certifications about the product’s U.S. regulatory status and FDA’s direct knowledge.

Omitting Required Supporting Documents: Submitting Form 1932 without necessary attachments prevents the FDA from verifying the request. Applications missing approval letters, device clearances, or requested certification language are returned as incomplete. This adds two to three weeks to the processing timeline while the applicant gathers and resubmits documents.

Failing to Verify Manufacturing Compliance Status: Requesting a certificate for a facility with outstanding warning letters or regulatory violations leads to certificate denial. Before submitting the request, check the FDA’s Warning Letters database and the Import Alerts list to confirm the facility has no compliance issues. If problems exist, resolve them before requesting certification.

Using Incorrect Fee Amounts: Submitting payment that does not match the current fee schedule causes processing delays. The FDA returns applications with insufficient payment and does not begin processing until correct payment is received. Check the current year’s fee schedule each time you submit a request, as fees change annually.

Missing Signature or Authorization: Submitting unsigned forms or having someone without proper authority sign the application invalidates the request. The person signing must be an authorized representative of the company with knowledge of the product and facility. Include a statement of authorization if the signer is not a corporate officer.

Requesting Certificates Too Early: Submitting requests before products receive FDA approval or before facilities complete registration results in rejection. Wait until all regulatory requirements are met and confirmations are received before requesting export certification. The FDA cannot certify future approvals or pending applications.

Providing Incomplete Destination Information: Failing to specify the exact destination country or listing only a region creates problems for foreign customs authorities. Be specific about the country receiving the shipment, even if products will later redistribute to other nations. Each country’s import requirements differ, and the certificate must match the first destination’s needs.

Ignoring Country-Specific Requirements: Submitting generic certification requests without researching what the destination country requires leads to incomplete certificates. Different nations need different certification statements, and a certificate that satisfies one country may be insufficient for another. Contact the foreign regulatory authority or consult with an import specialist in the destination country before requesting the certificate.

Comparing Export Certificate Types

The FDA issues several types of export certificates beyond Form 1932. Understanding the differences helps companies select the correct certification for their situation.

Form 1932 serves as the general-purpose export certificate for all FDA-regulated products. It provides maximum flexibility in certification language and can address unique requirements from any foreign government.

The Certificate of Pharmaceutical Product follows the World Health Organization’s standardized format. Many countries prefer this format for drugs because it contains specific information fields recognized internationally. However, the rigid format limits customization of certification statements.

The Certificate for Export specifically addresses products exported under Section 802 that are not approved for U.S. marketing. This certificate clearly states the product’s unapproved status while confirming the FDA permits its export to meet foreign requirements.

The Certificate of Free Sale verifies that a product is legally sold in the United States without restrictions. This differs from Form 1932 because it focuses on commercial availability rather than regulatory approval status.

Do’s and Don’ts for Form 1932 Requests

Following best practices increases the likelihood of timely certificate issuance and reduces costly errors.

Do’s

Do verify current FDA approval or registration status before requesting a certificate. Check the FDA databases to confirm that products maintain active approval and facilities hold valid registrations. A product approval withdrawn three months ago cannot receive certification, and discovering this after submitting the request wastes time and money. The verification takes fifteen minutes but prevents weeks of delays.

Do contact the foreign regulatory authority to obtain exact certification language. Many countries provide specific statements they require on certificates, and using their exact wording ensures acceptance. Generic certification requests may produce certificates that satisfy FDA requirements but fail to meet the foreign government’s needs. Requesting specific language prevents resubmission and reduces overall processing time.

Do submit requests well in advance of shipment deadlines. Standard processing takes up to twenty business days, and rush processing is not always available for complex requests. Planning for a thirty-day processing window provides a safety margin for unexpected questions or document requests. Last-minute certificate requests often result in delayed shipments and additional expedite fees.

Do maintain copies of all submitted documentation. Keep complete records of the application, supporting documents, payment confirmations, and correspondence with the FDA. If questions arise or resubmission becomes necessary, having copies readily available speeds the resolution process. Electronic copies stored in cloud systems ensure accessibility even if local files are lost.

Do review the completed form multiple times before submission. Simple errors like transposed digits in an application number or misspelled facility names cause rejections that could be avoided through careful review. Having a second person review the application catches mistakes the original preparer might miss. This extra ten-minute review prevents two-week reprocessing delays.

Do track certificate expiration dates for recurring exports. Many countries accept export certificates for only six or twelve months, requiring new certificates for continuing shipments. Maintaining a tracking system for certificate expiration prevents shipment disruptions when certificates expire unexpectedly. Set calendar reminders sixty days before expiration to allow time for renewal requests.

Do establish relationships with customs brokers familiar with destination country requirements. Experienced brokers understand what certificates foreign customs officials expect and can identify potential problems before shipment. Their expertise reduces the risk of certificate rejection at the border even when the FDA has issued technically correct documentation.

Don’ts

Don’t wait until products are ready to ship before requesting certificates. Beginning the certification process only when products await shipment creates intense time pressure that leads to errors. The stress of urgent deadlines increases the likelihood of submitting incomplete applications or requesting inappropriate certifications. Start the process when export plans solidify, not when trucks are loading.

Don’t assume the same certificate works for all destination countries. Each nation has unique import requirements, and a certificate that perfectly satisfies European Union needs may be inadequate for Asian markets. Canada’s requirements differ from Mexico’s despite both being NAFTA partners. Research each destination’s specific requirements and request appropriate certifications for each market.

Don’t request certifications for products or facilities with known compliance issues. Attempting to obtain certificates while warning letters remain outstanding or import alerts are active results in rejection. The FDA will not certify compliance when its own records show violations. Resolve all regulatory issues before requesting certification to avoid wasted fees and processing time.

Don’t use vague or ambiguous language in certification requests. Asking the FDA to certify that a product “meets all applicable standards” without specifying which standards creates confusion. The FDA needs precise certification statements to evaluate whether it can truthfully make the requested statements. Vague requests result in generic certificates that may not satisfy foreign authority requirements.

Don’t submit multiple requests for the same product to different FDA offices. Some companies attempt to expedite processing by submitting duplicate requests to various FDA centers or divisions. This creates confusion in FDA systems, may result in conflicting certificates, and can trigger fraud investigations. Submit one properly completed request to the designated processing office and follow up through appropriate channels.

Pros and Cons of Different Submission Methods

The FDA accepts Form 1932 requests through multiple channels, each with distinct advantages and disadvantages.

Electronic Submission Through FDA Portal

Pros:

• Faster processing acknowledgment occurs within twenty-four hours, confirming the FDA received the request and providing a tracking number for status checks
• Reduced risk of lost documents because electronic systems maintain permanent records and do not rely on physical mail delivery
• Immediate payment confirmation through integrated electronic payment systems eliminates questions about whether payment was received or credited correctly
• Environmental benefits from paperless submission align with corporate sustainability goals and reduce physical storage needs
• Easier document attachment allows uploading multiple supporting files without concerns about file size limitations that affect email submissions

Cons:

• Technical difficulties with file uploads or system compatibility can prevent submission during critical timeframes when certificates are urgently needed
• Limited customer support for electronic system problems may leave users without help during non-business hours or federal holidays
• Learning curve for first-time users requires time investment to understand the portal navigation and file format requirements
• System maintenance periods occasionally block access during scheduled or emergency downtime, preventing time-sensitive submissions
• Security requirements like complex passwords and multi-factor authentication may create access difficulties for users unfamiliar with strict cybersecurity protocols

Paper Mail Submission

Pros:

• Familiar process for companies without electronic submission experience reduces training needs and implementation complexity
• No technical requirements eliminate concerns about system compatibility, internet connectivity, or digital signature capabilities
• Physical documentation provides tangible proof of submission with certified mail return receipts
• Simple for small companies without dedicated IT infrastructure or electronic document management systems
• Accessible to all regardless of technological sophistication or digital infrastructure availability

Cons:

• Slower processing because mail delivery adds three to five days before the FDA receives the request, delaying the start of review
• Risk of mail loss means applications may never arrive, requiring resubmission and wasting the initial processing fee
• Delayed payment posting when paying by check extends processing time while the FDA’s accounting office credits the payment
• No immediate confirmation leaves applicants uncertain whether the FDA received the submission until acknowledgment letters arrive weeks later
• Environmental impact from paper consumption and transportation emissions conflicts with sustainability objectives

Expedited Courier Service

Pros:

• Tracked delivery through courier systems provides real-time location updates and confirmed delivery times with recipient signatures
• Faster than regular mail reduces initial delivery time from five days to one or two days
• Delivery guarantees offer refunds or redelivery if the courier fails to meet promised delivery timeframes
• Secure chain of custody maintains document integrity through the entire delivery process with tamper-evident packaging
• Accessible proof of delivery through online systems allows immediate verification that the FDA received the application

Cons:

• Additional expense for courier services adds fifty to one hundred dollars to the total certification cost
• No processing time reduction because the FDA’s internal review timeline remains the same regardless of delivery method
• Limited value for standard requests when normal processing meets timeline needs makes the extra courier cost unnecessary
• Coordination challenges for international companies shipping applications from overseas locations to U.S. courier services
• Marginal benefit over electronic submission which provides faster, cheaper confirmation without courier fees

State-Level Interactions with Federal Export Requirements

While FDA Form 1932 addresses federal regulatory requirements, state-level regulations can affect export processes in specific situations.

State Pharmacy Board Requirements

State pharmacy boards regulate pharmacy operations within their jurisdictions, and some states impose additional requirements on facilities that export pharmaceutical products. California requires pharmacies that export drugs to obtain a sterile compounding license if they prepare injectable medications, even for export purposes.

These state requirements do not replace federal export certificates but operate alongside them. A pharmaceutical manufacturer in California must maintain both FDA compliance for federal export authorization and California pharmacy board compliance for state operating permission.

New York requires pharmacies exporting controlled substances to notify the state Bureau of Narcotic Enforcement before shipment. This notification requirement supplements federal Drug Enforcement Administration export controls rather than duplicating them.

State requirements typically focus on facility operation and professional licensing rather than product certification. The FDA Form 1932 certifies product regulatory status, while state licenses confirm the facility’s legal authority to operate within the state.

State Medical Device Manufacturing Permits

Some states require device manufacturers to obtain state-level permits or licenses separate from FDA registration. Massachusetts requires medical device manufacturers to register with the state Department of Public Health regardless of FDA registration status.

These state registrations address public health monitoring and emergency preparedness within the state. During disease outbreaks or medical emergencies, states need to know which facilities can produce critical medical supplies.

State permits do not appear on FDA export certificates because they represent state rather than federal authority. However, foreign governments sometimes request confirmation of state licensing when evaluating manufacturing quality systems.

Export certificate requests should include state permit information in the supporting documentation section if the destination country specifically requests it. The FDA will not verify state permits but can acknowledge their existence if properly documented.

State Food Safety Programs

States operate food safety programs that supplement FDA oversight through cooperative agreements. California’s food safety program conducts inspections of food facilities on behalf of the FDA under the Manufactured Food Regulatory Program Standards.

When a state inspector conducts an FDA inspection under these cooperative agreements, the results carry the same weight as FDA-conducted inspections. Export certificates can reference these inspections because they represent federal regulatory authority exercised through state personnel.

Food facilities must maintain compliance with both state and federal requirements. A facility that meets FDA standards but violates state food safety codes may face state enforcement actions that affect export eligibility.

The relationship between state and federal food regulation requires coordination when requesting export certificates. Facilities should verify they have no outstanding state violations before claiming compliance on federal export certificate applications.

State Import-Export Licensing

Some states require import-export licenses for certain product categories, particularly controlled substances and hazardous materials. These licenses control product movement across state borders and international boundaries.

State import-export licenses differ from FDA export certificates in scope and purpose. The state license authorizes the business to engage in import-export activities, while the FDA certificate verifies product regulatory status for foreign governments.

Companies need both authorizations when state requirements apply. A pharmaceutical distributor in Texas exporting controlled substances must hold a Texas Department of Public Safety import-export license and obtain FDA export certification for each shipment.

The state license demonstrates business authority to conduct export operations, while the FDA certificate provides product-specific information that foreign governments require. Neither document substitutes for the other in states with both requirements.

Detailed Processing Timeline and Follow-Up Procedures

Understanding the certificate processing timeline helps companies plan exports effectively and know when to follow up on pending requests.

Initial Receipt and Acknowledgment Phase

The FDA receives export certificate requests and logs them into the processing system within two to five business days. Electronic submissions receive automated acknowledgment within twenty-four hours, while paper submissions take longer to enter the system.

During this phase, administrative staff verify that applications include all required elements. They check for signatures, payment, and basic completeness. Applications missing critical components receive rejection notices explaining what must be added.

The acknowledgment notice includes a tracking number and estimated completion date. This tracking number allows applicants to check status through the FDA’s inquiry system without calling or emailing.

Companies should retain the tracking number and reference it in all communications about the certificate request. Without this number, FDA staff must search for applications manually, which delays responses to status inquiries.

Review and Verification Phase

After initial receipt, the application moves to subject matter experts who verify the specific information requested. For drug certificates, pharmaceutical reviewers check approval status, manufacturing compliance, and certification accuracy.

Reviewers access FDA databases to confirm that products match submitted information. They verify NDA numbers, check inspection dates, review compliance history, and ensure requested certifications align with documented facts.

This phase takes the majority of processing time because reviewers often handle multiple requests simultaneously while managing other regulatory responsibilities. Complex certifications requiring research into unusual approval pathways or special regulatory categories take longer than straightforward approval confirmations.

If reviewers identify discrepancies or have questions about the request, they contact the applicant for clarification. These information requests pause the processing timeline until the applicant responds with satisfactory explanations or corrections.

Certificate Preparation and Quality Control

Once verification is complete, staff prepare the actual certificate document. They transfer information from the application to the official certificate template, ensuring accuracy and proper formatting.

Quality control reviewers check the prepared certificate against the original application and FDA records. This dual-review process prevents errors that could invalidate the certificate or create problems for the applicant.

Certificates receive official FDA seals and authorized signatures. For electronic submissions, digital signatures provide authentication. For paper submissions, original signatures appear on physical certificate documents.

The preparation and quality control phase typically takes two to three business days once verification is complete. Rush processing expedites this phase by prioritizing the certificate ahead of standard requests.

Delivery and Follow-Up

Completed certificates are delivered through the method specified in the application. Electronic submissions receive certificates via secure email or portal download. Paper submissions receive certificates through postal mail to the address provided.

Companies should verify receipt immediately and review certificates for accuracy. Any errors or discrepancies should be reported to the FDA within five business days of receipt to expedite corrections.

The FDA maintains copies of all issued certificates in its records system. If the original certificate is lost or damaged, companies can request certified copies for a reduced fee. These copies carry the same legal weight as originals for foreign government purposes.

Handling Processing Delays

Standard processing occasionally extends beyond the estimated completion date. Common reasons include high request volumes, complex certification requirements, or questions about product regulatory status.

Companies should wait until five business days after the estimated completion date before contacting the FDA about delays. Many applications complete on the estimated date or within a few days, and premature inquiries burden FDA staff without accelerating processing.

When contacting the FDA about delays, provide the tracking number, submission date, and product information. Explain any urgent timeline needs, such as imminent shipment deadlines or foreign regulatory filing dates.

The FDA prioritizes applications with documented urgent needs when possible. However, rush processing fees apply to expedited handling, and companies cannot obtain rush processing through delayed standard applications without paying additional fees.

Country-Specific Export Certificate Requirements

Different destination countries impose varying requirements on export certificates, and understanding these differences prevents shipment delays at foreign customs.

European Union Member States

The European Union accepts FDA export certificates as part of pharmaceutical and medical device registration processes. However, EU regulatory frameworks require specific information that must appear on certificates.

For pharmaceuticals, the EU wants confirmation that products are manufactured in facilities inspected under the FDA’s cGMP program within the past two years. The certificate should specify the inspection date and outcome.

Medical devices entering the EU market require certificates confirming FDA classification and clearance or approval pathway. The EU uses a different classification system, so certificates should explain the U.S. classification and comparable EU category.

Some EU member states require certificates in specific languages. While the FDA issues certificates only in English, certified translations may be necessary for countries like France or Spain where customs officials require native language documentation.

Japan’s Unique Documentation Needs

Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) requires extremely detailed export certificates that specify manufacturing processes, quality control procedures, and post-market surveillance systems.

The certificate must confirm that manufacturing facilities comply with Japanese GMP standards or demonstrate equivalence to these standards through FDA inspection findings. This requires including detailed inspection information in the certification request.

Japan requires separate certificates for each dosage form and strength of pharmaceutical products. A drug available in 10mg and 20mg tablets needs two distinct certificates, each specifying the exact formulation and manufacturing details.

Medical devices exported to Japan require certificates explaining the predicate device comparison for 510(k) clearances. Japanese regulators evaluate whether the predicate device provides an appropriate comparison for their own assessment process.

China’s Registration Certificate Requirements

China’s National Medical Products Administration requires export certificates as part of the registration process for imported drugs and devices. These certificates must address specific questions outlined in Chinese registration guidance.

For drugs, China wants confirmation of approval status, manufacturing site details, approved indications, and any post-market safety issues identified in the U.S. The certificate must disclose voluntary recalls, safety communications, or label changes resulting from adverse event reports.

Medical device certificates for China require extensive manufacturing information including quality management system certifications, material sourcing, and biocompatibility testing results. The level of detail exceeds typical export certificate content.

Chinese authorities increasingly request site inspection reports as supplements to export certificates. While the FDA cannot provide confidential inspection reports, it can issue certificates confirming inspection dates, outcomes, and general compliance findings.

Canada’s Mutual Recognition Considerations

Canada maintains close regulatory cooperation with the United States through mutual recognition agreements. Canadian authorities often accept FDA approval as evidence supporting Canadian licensing decisions.

Export certificates for Canada focus on confirming current regulatory status and compliance standing. Health Canada wants assurance that FDA-approved products maintain good standing without outstanding safety concerns or compliance violations.

For medical devices, Canada’s classification system aligns closely with FDA’s risk-based approach. Certificates should clearly identify the FDA classification and explain how it corresponds to Canadian classification categories.

Canada requires certificates to address any differences between U.S.-approved products and versions intended for Canadian sale. Label differences, language requirements, or formulation changes must be clearly explained.

Latin American Country Requirements

Latin American countries vary significantly in their export certificate requirements. Brazil’s ANVISA requires comprehensive certificates covering approval status, manufacturing compliance, and post-market surveillance.

Mexican regulatory authorities require certificates confirming that products are freely sold in the United States without restrictions. The certificate must explicitly state that the FDA has not withdrawn approval or imposed sales limitations.

Argentina requires certificates that address both federal FDA regulation and state-level oversight. The certificate should explain the relationship between federal and state regulatory authority when applicable.

Colombian authorities require certificates in Spanish, necessitating certified translation services. The FDA issues English-language certificates, and applicants must arrange professional translation before submitting documents to Colombian regulators.

Frequently Asked Questions

Can I request Form 1932 for a product still under FDA review?

No. The FDA cannot issue export certificates for products that have not completed the regulatory review process. Applications pending approval lack the verified status information that foreign governments require on certificates.

Does Form 1932 expire after a certain period?

No from the FDA’s perspective, but foreign countries often impose validity periods. Most nations accept certificates for six to twelve months from the issue date, requiring new certificates for shipments beyond that timeframe.

Can Form 1932 cover multiple products in one certificate?

No. Each product requires a separate certificate because foreign governments need specific information about individual products. Manufacturing facilities may appear on multiple certificates, but each product needs dedicated certification.

Is Form 1932 required for all international shipments?

No. Only countries that specifically request FDA certification require Form 1932. Many nations accept products without export certificates, particularly for non-medical items or products sold through international distributors.

Can third-party consultants submit Form 1932 on my behalf?

Yes, if they have proper authorization. The consultant must submit a signed letter of authorization from the manufacturer granting them permission to request certificates. The manufacturer remains responsible for accuracy.

What happens if my certificate contains errors?

The FDA will issue corrected certificates at no additional charge if the error resulted from agency mistakes. If the error stems from incorrect information in the application, a new request with the full fee is required.

Can I expedite Form 1932 processing without paying rush fees?

No under normal circumstances. The FDA requires rush processing fees for expedited handling. Exceptions exist only for humanitarian emergencies or public health crises, which require extensive documentation and justification.

Does Form 1932 guarantee foreign government approval?

No. The certificate verifies U.S. regulatory status but does not ensure foreign approval. Each country conducts its own review process, and certificates serve as supporting documentation rather than approval guarantees.

Can dietary supplements receive Form 1932 certification?

Yes, but with limitations. The FDA can certify that supplements comply with U.S. requirements under DSHEA, but cannot certify safety or efficacy because supplements do not require premarket approval.

Is Form 1932 needed for personal use shipments?

No. Personal use quantities shipped by individuals for non-commercial purposes generally do not require export certificates. Commercial shipments, regardless of size, need proper certification when destination countries require it.

Can Form 1932 be used for multiple shipments?

Yes, within the validity period accepted by the destination country. One certificate can support multiple shipments of the same product to the same country until the certificate expires.

What if my manufacturing facility changed after receiving approval?

You must update FDA records before requesting export certificates. Certificates must reflect current manufacturing locations, and outdated facility information will be detected during verification, causing rejection.

Does Form 1932 replace commercial invoices or shipping documents?

No. Export certificates supplement rather than replace standard shipping documentation. Commercial invoices, bills of lading, and customs declarations remain necessary for international shipments.

Can I request Form 1932 for investigational products?

Yes, for clinical trial purposes. The FDA issues special certificates for investigational products confirming IDE or IND status and authorizing export for specified research purposes.

Are electronic signatures acceptable on Form 1932?

Yes for electronic submissions through the FDA portal. Paper submissions require original handwritten signatures from authorized representatives.